In the meantime, there was a multicenter, randomized phase III trial (RATIFY) in 717 younger adult patients, which demonstrated a significant improvement in OS and EFS among AML patients with FLT3 mutation, when adding midostaurin to standard induction therapy. The gene discussed is FLT3; the disease is acute myeloid leukemia.